Free Trial

Biotricity Q3 2025 Earnings Report

Biotricity logo
$0.35 0.00 (-0.14%)
As of 04/4/2025 03:45 PM Eastern

Biotricity EPS Results

Actual EPS
-$0.05
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
$3.62 million
Expected Revenue
$3.30 million
Beat/Miss
Beat by +$320.00 thousand
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Q3 2025
Time
After Market Closes

Conference Call Resources

Remove Ads

Biotricity Earnings Headlines

H.C. Wainwright Sticks to Their Hold Rating for Biotricity (BTCY)
Biotricity expands IP portfolio with 14 new patents
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
Biotricity reports Q3 EPS (5c) vs. (34c) last year
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (OTCMKTS:BTCY), a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

View Biotricity Profile

More Earnings Resources from MarketBeat